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Abstract (250/250 max)
The adult subventricular zone (SVZ) stem cell niche has proven vital for discovering 
neurodevelopmental mechanisms and holds great potential in medicine for 
neurodegenerative diseases. Yet the SVZ holds a dark side - it can become tumorigenic. 
Glioblastomas can arise from the SVZ via cancer stem cells (CSCs). Glioblastoma and 
other brain cancers often have dismal prognoses since they are resistant to treatment. In 
this review we argue that the SVZ is susceptible to cancer because it contains stem cells, 
migratory progenitors and unusual inflammation. Theoretically, SVZ stem cells can convert 
to CSCs more readily than can postmitotic neural cells. Additionally, the robust long-
distance migration of SVZ progenitors can be subverted upon tumorigenesis to an 
infiltrative phenotype. There is evidence that the SVZ, even in health, exhibits chronic low-
grade cellular and molecular inflammation. Its inflammatory response to brain injuries and 
disease differs from that of other brain regions. We hypothesize that the SVZ inflammatory 
environment can predispose cells to novel mutations and exacerbate cancer phenotypes. 
This can be studied in animal models in which human mutations related to cancer are 
knocked into the SVZ to induce tumorigenesis and the CSC immune interactions that 
precede full-blown cancer. Importantly inflammation can be pharmacologically modulated 
providing an avenue to brain cancer management and treatment. The SVZ is accessible 
by virtue of its location surrounding the lateral ventricles and CSCs in the SVZ can be 
targeted with a variety of pharmacotherapies. Thus, the SVZ can yield aggressive tumors 
but can be targeted via several strategies.
Abbreviations
ASPP2, apoptosis-stimulating protein of p53 with signature sequences of ankyrin repeat-, 
SH3 domain-, and proline-rich region-containing protein 2; CD, complement of 
differentiation; CNS, central nervous system; CP, choroid plexus; CSC, cancer stem cell; 
CSF, cerebrospinal fluid; EGF, epidermal growth factor; EGFr, epidermal growth factor 
receptor; EPO, erythropoeitin; FGF2, Fibroblast growth factor 2; GBM, glioblastoma 
multiforme, GFAP, glial fibrillary acidic protein; G-CSF, granulocyte colony-stimulating 
factor; HGF, hepatocyte  growth factor; IDH1, isocitrate dehydrogeniase 1; IFN- gamma 
interferon; IGF-1, insulin growth factor-1; IL-10, interleukin 10; iPSC, induced pluripotent 
stem cell; NSC, neural stem cell; OCT4, octamer-binding transcription factor 4; PDGF, 
platelet-derived growth factor; PDGFr, platelet-derived growth factor receptor; RCAS, 
replication competent avian-like sarcoma; RMS, rostral migratory stream; ROS, reactive 
oxygen species; SCNT, somatic cell nuclear transfer; SDF-1, stromal cell derived factor-1; 
SHH, sonic hedgehog; SVZ, subventricular zone; TAP, transit amplifying progenitor; 
TMEV, Thelier's murine encephalomyelitis virus; TNFα, tumor necrosis factor-alpha; 
VEGF, vascular endothelial growth factor.
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1. Introduction
The past two decades have witnessed an explosion of information demonstrating 
that endogenous tissue stem cell niches can harbour cancer stem cells. Many of the 
molecular regulatory pathways driving normal development and maintaining tissue 
homeostasis can be subverted in cancer (Canoll and Goldman, 2008). The mammalian 
brain contains three neural stem cell (NSC) niches that continuously produce new neurons 
throughout life; the subventricular zone (SVZ) lining the lateral ventricle, the subgranular 
zone (SGZ) of the hippocampal dentate gyrus and the mediobasal hypothalamus (Alvarez-
Buylla and Lim, 2004; Recabal et al., 2017). Hypothalamic neurogenesis is the most 
recently discovered niche, is the most poorly understood and has not been confirmed in 
humans. Neuroblasts generated in the SGZ move a short distance to the granular cell 
layer where they differentiate into dentate gyrus granule neurons that are thought to 
influence memory (Cameron et al., 1993; Lacar et al., 2014). Hippocampal and 
hypothalamic cancers are rare and less is known about inflammation in these niches than 
in the SVZ. Therefore, in this review we will concentrate on the SVZ and mostly ignore the 
hippocampal and hypothalamic niches. 
The adult SVZ generates the largest number of cells of the three niches, mostly 
producing neuroblasts (Fig. 1D). The newborn cells travel long distances from the SVZ via 
the rostral migratory stream (RMS) into the olfactory bulbs (OB) where they differentiate 
into periglomerular or granule local interneurons (Doetsch and Alvarez-Buylla, 1996). The 
SVZ lines the lateral ventricles and multiciliated ependymal cells separate the SVZ from 
the circulating cerebrospinal fluid (CSF). The SVZ niche contains multiple cell types (type 
B, C and A cells), which also include microglia, the primary immune cells of the brain 
(Doetsch et al., 1997; Dulken et al., 2017). Type B cells have astrocytic characteristics and 
are subdivided into type B1 and B2 cells. B1 cells have direct contact with the lateral 
ventricle (LV) and act as self-renewing neural stem cells whereas B2 cells do not maintain 
direct contact with the LV and act as niche astrocytes. Type B1 cells give rise to transit 
amplifying progenitors (TAP) (C cells) that actively divide and generate immature 
neuroblasts (A cells) that migrate to the OB (Doetsch et al., 1999; Garcia et al., 2004; Ihrie 
and Alvarez-Buylla, 2011). In addition to neurons, the postnatal SVZ generates 
progenitors that migrate from the SVZ throughout the forebrain and differentiate into 
astrocytes and oligodendrocytes (Levison and Goldman, 1993). A central theme of our 
review is that this developmental event is recapitulated and dysfunctional in SVZ cancers. 
The human SVZ is somewhat different compared to its rodent counterparts. In 
infants the human SVZ generates neuroblasts that migrate not only to the olfactory bulb 
but also into the cerebral cortex (Paredes et al., 2016; Sanai et al., 2011). In the adult 
human there is little evidence for migration of neuroblasts from the SVZ to the OB (Sanai 
et al., 2004). However the adult human SVZ is thought to generate progenitors that  
migrate laterally to the caudate nucleus and differentiate into interneurons (Ernst et al., 
2014). The discovery of adult human neurogenesis has injected great hope into the idea 
that stimulating these stem cells for endogenous repair of brain injuries or 
neurodegenerative diseases could be a viable therapeutic intervention (Young et al., 
2011a). It is well documented that stem cells and progenitors increase proliferation in 
response to animal models of neurological disease as well as in human patients and that 
cells born in the SVZ migrate actively towards the injuries (Chang et al., 2016; Dizon and 
Szele, 2005; Szele and Chesselet, 1996). The cells generated by the neurogenic niches 
can be neuroprotective via generation of growth factors and dampening of inflammation 
(Pluchino et al., 2009; Pluchino et al., 2005). 
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Nevertheless, Murphy's law seems to exist in biology and "when something can go 
wrong it will". The most dramatic example of this in the SVZ is that instead of contributing 
to regeneration, the niche generates and/or supports cancer. The cancer stem cell (CSC) 
hypothesis suggests that a tumor is maintained over time by a small subset of cancer cells 
with stem cell-like properties, i.e. unlimited self-renewal, multipotency and tumor initiating 
capacity. Although controversial, the existence of a subpopulation of cancer cells endowed 
with these properties has been described in some non-solid and solid tumors, including 
brain cancer (Beier et al., 2007; Chen et al., 2010; Clarke et al., 2000; Galli et al., 2004; 
Mazzoleni et al., 2010; Singh et al., 2004). Consequently, adult SVZ NSCs and 
progenitors have been suggested as a source for CSCs. The SVZ niche is thought to be a 
tumor reservoir for a range of high grade gliomas, including adult glioblastoma, the most 
common and most malignant glioma (Fig. 2). Resistance of glioblastoma to therapy and its 
rapid recurrence are believed to be caused by CSCs in the tumor. Notably, gliomas in 
close contact with the SVZ are more aggressive compared to ones distant from this site 
(Adeberg et al., 2014a; Chaichana et al., 2008; Gollapalli et al., 2017; Jafri et al., 2013; 
Mistry et al., 2017a; Mistry et al., 2017b; Young et al., 2011b). These tumors show 
increased recurrence and resistance to therapy, further suggesting they arise from and are 
maintained by CSCs (Chen et al., 2015; Sonoda et al., 2014). The evidence for SVZ-
associated tumors arising from CSCs is still rather indirect, but as described in later 
sections of our review this possibility is testable.
Most tumors are associated with inflammation, and despite its heterogeneity, 
inflammation is a cancer risk factor in general which can exacerbate malignancy. It is well-
established that the SVZ niche is bathed in a unique soup of chemokines, cytokines and 
growth factors. In this review we will explore less well-known evidence that regulation of 
inflammation in the SVZ is unusual and that this can contribute to SVZ tumorigenesis. 
Although the brain has long been considered to be "immune-privileged", this concept is 
now less accepted (Engelhardt et al., 2017), and in fact, the SVZ and adjacent choroid 
plexus seem to be a hot-spot of inflammation and immune activity. Secreted molecules  
produced by different SVZ cells result in complex regulation of proliferation, differentiation 
and survival. Interestingly, many of the molecules produced by the SVZ niche are identical 
to those released by inflammatory cells which drive tumorigenesis. These include the 
epidermal growth factor (EGF) and the angiogenic growth factors vascular endothelial 
growth factor (VEGF) and fibroblast growth factor 2 (FGF2) in addition to chemokines and 
cytokines that amplify the inflammatory state. In uncontrolled conditions the signaling 
molecules produced in the SVZ could generate a response resembling that present in  
chronic inflammatory tissue. Hence an intriguing hypothesis is that the “inflammatory” 
signals released in the SVZ may be important in creating and maintaining CSCs. We finish 
the review by suggesting that the location of the SVZ predisposes it to be a target for 
cancer therapeutic interventions.
2. The Inflammatory Subventricular Zone 
Microglia and inflammation regulate various aspects of brain development via direct 
sculpting of cells and synapses and by altering the cytokine milieu. Microglia phagocytize 
neural progenitor cells during cerebral cortex development in rodents and primates and 
can be modulated by anti-inflammatory agents (Cunningham et al., 2013). Microglia are 
also known to consume neural progenitor cells in the hippocampal SGZ and thereby 
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regulate their numbers (Sierra et al., 2010). Could microglia also be targeted for clearance 
of CSCs or other downstream transformed cells? Neither this question nor whether 
microglia phagocytize SVZ cells in health or disease is well understood. What is known 
however is that SVZ inflammation is constitutively semi-activated, that it is unusually 
regulated, and that the SVZ lines the CSF-brain barrier, potentially exposing it to 
pathogens. We will describe these features and also data showing that the choroid plexus 
harbours immune cells poised for activation and that it influences the molecular 
composition of the CSF.
Microglia also sculpt circuits during neural development via synaptic phagocytosis 
which helps eliminate unused circuits (Schafer et al., 2012). An interesting aspect of SVZ 
anatomy is that many axon terminals abut the niche without entering it whereas others 
directly enter the niche. Dopaminergic nigrostriatal axon terminals seem to have a barrier 
at the SVZ-striatal interface (Ramaswamy et al., 2005). Nevertheless dopamine released 
by nigrostriatal neurons diffuses into the SVZ and binds to dopamine receptors, thereby 
regulating neurogenesis (Hoglinger et al., 2004; Kim et al., 2010). In contrast, there is 
evidence that axon terminals of striatal GABAergic, septal cholinergic and serotonergic 
neurons are all found amongst SVZ cells (Banasr et al., 2004; Paez-Gonzalez et al., 2014; 
Young et al., 2014b). The neurotransmitters released by these neurons regulate SVZ 
proliferation and other functions (Banasr et al., 2004; Paez-Gonzalez et al., 2014; Young 
et al., 2014b). Recently, pro-opiomelanocortin (POMC) hypothalamic neurons were shown 
to project axon terminals specifically into the anterior ventral SVZ and thereby regulate 
hunger-mediated neurogenesis (Paul et al., 2017). Thus it may be that during 
development as in homeostasis, SVZ microglia phagocytize axonal inputs to limit their 
density or control their location in the SVZ. We predict that this process occurs and that it 
may be dysregulated in cancer, changing the balance of neurotransmitters, SVZ 
proliferative homeostasis and ultimately contributing to disease progression. 
2.1.The SVZ is a unique inflammatory niche at the cellular level
Several lines of research over the past decade indicate that in contrast to the rest of 
the brain, the SVZ is constitutively semi-inflamed (Goings et al., 2006). Inflammation is 
quite differently regulated during embryogenesis and early life, and given that the SVZ is 
neurodevelopmentally active throughout life, this is not completely surprising. Two to five 
percent of SVZ cells are microglia and they are evenly distributed amongst the other SVZ 
cells. Electron microscopy shows that their processes make extensive contacts with all cell 
types in the niche and also with ependymal and RMS cells (Goings et al., 2006; Yang et 
al., 2004). In healthy mice, SVZ microglial expression of CD45 and other microglial 
markers such as isolectin B4 is higher than in other brain regions (Goings et al., 2006). 
SVZ microglia also proliferate at higher rates (~5 fold or more) compared to corpus 
callosum or striatal microglia, respectively (Goings et al., 2006). In contrast to the SVZ, 
hippocampal SGZ microglia are not semi-inflamed in homeostasis (Goings et al., 2006) 
whereas there is some evidence suggesting the hypothalamic NSC niche exhibits 
constitutive inflammation (Zhang et al., 2013). 
More recent studies have also found that microglia in the SVZ exhibit different 
characteristics from microglia found in the adjacent parenchyma. Young postnatal rat SVZ 
microglia expressed high levels of CD68 and had amoeboid morphology, both indicators of 
activation (Shigemoto-Mogami et al., 2014). Adult mouse microglia in the SVZ express 
lower levels of purinergic receptors compared to other microglia and are unable to respond 
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to ATP with chemotaxis (Ribeiro Xavier et al., 2015a). As was observed in earlier work 
(Goings et al., 2006), murine SVZ microglia appeared to be in a morphological state of 
semi-activation with enlarged cell bodies and processes that were shorter and thicker than 
striatal or cortical microglia (Ribeiro Xavier et al., 2015a). Recently it was shown that the 
anti-inflammatory drug minocycline increases SVZ neurosphere proliferation and stem cell 
numbers, possibly in a microglia-independent manner suggesting that anti-inflammatory 
agents may directly modulate the SVZ niche (Kuroda et al., 2017). A major remaining 
question however, is whether the human SVZ also harbours activated or semi-activated 
microglia and if it is also constitutively semi-inflamed. If so, then this may contribute to the 
generation and evolution of SVZ-derived cancer.
Complementing the microglial differences in homeostasis, multiple experiments 
show that SVZ inflammation in response to injury is difficult to predict and differs from 
surrounding inflammation. Cerebral cortex injury robustly activated microglia in the corpus 
callosum and in the striatum but remarkably, not in the immediately adjacent SVZ, even in 
regions of the niche that were close to the injury (Goings et al., 2006). This study was the 
first to point out that inflammation is unusually regulated in the SVZ and that the cellular 
response therein is dramatically different from adjacent regions of the brain. Although 
microglia were resistant to activation after cortical injury, SVZ astrocytes exhibited 
increased glial fibrillary acidic protein (GFAP) expression which is indicative of astrocytic 
inflammation (Sundholm-Peters et al., 2005), suggesting that though microglial 
inflammation is unique in the SVZ, astrocytic inflammation may be regulated similarly to 
the parenchyma. In line with this notion, the middle cerebral artery occlusion (MCAO) 
model of cortical and striatal stroke caused marked astrocytic reactivity in these regions as 
well as in the SVZ, however it did not change the percentage of mitotic microglial cells in 
the SVZ, which was only one hundred microns or so from the edge of the lesion (Young et 
al., 2013). Inflammation is often associated with apoptosis and indeed MCAO caused 
robust apoptosis in the striatum but not in the SVZ (Young et al., 2013). We do not know if 
cell death in glioblastoma or other SVZ-related cancers is differentially regulated in the 
niche compared to the rest of the brain. However apoptosis is an important event in 
regulating cancer, making this question important for future in-depth study. 
Several other studies confirm the SVZ has unpredictable inflammatory responses to 
disease, with the example of multiple sclerosis models being the most pertinent (Goings et 
al., 2008; Hillis et al., 2016; James et al., 2016). In contrast to the cortical and stroke-like 
lesions just mentioned, a viral model of chronic progressive demyelination (Thelier's 
murine encephalomyelitis virus, TMEV) targeted the SVZ with early, predictable, 
consistent and massive inflammation even though inflammation was stochastic in the rest 
of the CNS (Goings et al., 2008; James et al., 2016). Whereas the large majority of CD45+ 
immune cells in the SVZ are microglia, TMEV induced massive infiltration of T cells into 
the niche (James et al., 2016). In sharp contrast to TMEV, mild reversible demyelination 
achieved by cuprizone toxicity caused inflammation in the corpus callosum and striatum 
but not in the immediately adjacent SVZ. There was no evidence that inflammation had 
increased compared to healthy controls, and in fact the number of CD45+ cells was 
decreased after cuprizone (Hillis et al., 2016). As well, the number of mitotic cells, which is 
associated with gliosis in brain inflammation increased in the corpus callosum and striatum 
immediately adjacent to the SVZ, but decreased in the stem cell niche after cuprizone 
demyelination (Hillis et al., 2016). 
Much work has been carried out in the last two decades to understand the SVZ 
response to injury and disease in the hope of optimizing the endogenous neuro-
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regenerative capacity of the niche (Chang et al., 2016; Dizon and Szele, 2005; Kim and 
Szele, 2008; Young et al., 2011a). Yet only a minority of these studies has considered how 
the regulation of inflammation impacts the SVZ's response to pathology. In light of  
findings emphasizing the importance of inflammation in the SVZ further studies will have to 
pay closer attention to this in the context of injury. Cancer usually induces inflammation but 
the data above suggest that different types of cancer may increase, have no effect or even 
decrease SVZ inflammation. It will be important for new studies to discern the range of 
inflammatory responses in the SVZ to different types of cancer.
2.2. Immune cells enter the brain through the SVZ 
Microglia are the resident macrophages in the brain and are involved in active 
immune responses against infection and injury. In rodents, macrophages that are 
generated in the yolk sac at embryonic day 8 (E8) start to colonize the neuroepithelium 
from E9/E9.5 and give rise to embryonic microglia (Ginhoux et al., 2013). The blood-brain 
barrier (BBB) starts to appear at E13.5 isolating the CNS from peripheral macrophages. 
However, older data suggested that the SVZ is a major route of entry into the brain of 
immune cells during normal perinatal periods of development (Mohri et al., 2003). 
Resident microglia in the brain parenchyma expand through local proliferation during late 
embryonic to early postnatal development. In adulthood, bone marrow (BM) derived 
macrophages may cross the BBB during inflammation in order to supplement local 
microglial populations in the brain (Ginhoux et al., 2013). After cortical injury, peripheral 
macrophages labelled with fluorescent microbeads entered the brain and SVZ in a few 
hours and then equally rapidly exited (Goings et al., 2006). The same lesions induced SVZ 
microglia to migrate towards the cortex (Goings et al., 2006). Systemic inflammation may 
trigger migration of leukocytes from the bloodstream into the CNS where they differentiate 
into resident macrophages or dendritic cells. The likelihood of leukocyte infiltration into the 
brain may rely on the blood-brain barrier, which is developmentally regulated, with a 
gradual increase in permeability with age. The blood-brain barrier collectively describes 
four main interfaces between the CNS and the periphery: blood-brain barrier, blood-CSF 
barrier, outer CSF-brain barrier and inner CSF-brain barrier. The blood-CSF barrier at the 
choroid plexus (CP) has higher permeability than the other barriers (Stolp et al., 2005), 
and the SVZ is located adjacent to the choroid plexus. Interestingly, CD45+ immune cells 
can be observed with processes that span the choroid plexus and the SVZ (Goings et al., 
2006). Therefore, infiltration of systemic molecules or cells is likely to be highly specialized 
in the SVZ region.
2.2.1. The choroid plexus flanks and influences the SVZ 
The CP, a thin epithelial tissue located in the ventricular system, has a high 
secretory capacity and produces the majority of the CSF in the vertebrate brain. The 
choroid plexus is mainly composed of a single layer of epithelial cells surrounding a 
stromal core of fenestrated blood vessels, fibroblasts and immune cells such as 
macrophages and dendritic cells. The tight junctions between adjacent epithelial cells 
prevent paracellular passage of blood cells into the CSF (Falcao et al., 2012). As such the 
choroid plexus comprises the blood-CSF barrier. However, the epithelial cells express 
several transporters that allow the passage of water, ions and small molecules including 
nutrients and vitamins. In addition, CP epithelial cells express receptors for various 
molecules including neurotransmitters, cytokines and toxins that affect downstream 
signaling pathways and proteins secreted from the choroid plexus (Falcao et al., 2012). 
The CP also harbours specialized T cells that respond to brain antigens as well as signals 
Progress in Neurobology  Al-Shammari et al., 2018 Cancer and Inflammation in the SVZ  
9
from the circulation suggesting it may be a good target for immune modulation (Baruch 
and Schwartz, 2013; Schwartz and Baruch, 2014). Despite these insightful observations, 
very little is known about CP immune activation during SVZ oncogenesis and how the 
specialized T cells in the CP may influence SVZ tumorigenesis. 
SVZ neural stem cells or type B1 cells are located immediately beneath the 
ependymal layer that surrounds the lateral ventricles. Type B1 cells maintain direct contact 
with the circulating CSF through a short non-motile apical cilium that extends towards and 
has direct contact with the lateral ventricles. Of interest, the choroid plexus releases 
various factors into the CSF that support the recruitment and proliferation of SVZ neural 
stem cells and their progeny (Silva-Vargas et al., 2016). This is conceptually similar to the 
effects of embryonic CSF on brain development (Lehtinen et al., 2013; Lehtinen and 
Walsh, 2011). The choroid plexus secretome normally changes throughout life which 
especially affects SVZ neural stem cells under basal conditions (Silva-Vargas et al., 2016). 
During peripheral inflammation, choroid plexus secretion is changed in ways that ultimately 
affect CSF composition (Marques et al., 2008; Marques et al., 2009). Although previous 
studies demonstrated the impact of neuroinflammation in the SVZ stem cell niche (Liu et 
al., 2013; Pluchino et al., 2008), it remains unclear whether inflammation-induced 
molecular changes in the choroid plexus per se directly affect SVZ cells during postnatal 
development. In particular, it would be interesting for future studies to determine whether 
disrupted secretion from the choroid plexus per se is directly involved in the progression of 
pathological conditions such as brain cancer. 
2.3.SVZ inflammation at the molecular level 
Several lines of evidence suggest that inflammation regulating-molecules are 
expressed in the SVZ. A few groups have used RNAseq to determine levels of 
heterogeneity in the SVZ lineage and have elucidated transcriptional regulation of these 
states. Overall they have shown that there are several more states of stem cell quiescence 
versus activation than previously appreciated, but they have also contributed insights into 
how SVZ inflammation regulates this transition. Single cell RNAseq demonstrated that 
after brain ischemia, gamma interferon (IFN-) induces dormant stem cells to enter an 
activated state (Llorens-Bobadilla et al., 2015). Another recent single-cell RNAseq study 
indicated that SVZ cells cultured as neurospheres expressed higher levels of genes 
associated with inflammation such as Fas and Ifitm3, and cytokine signaling than did in 
vivo SVZ cells (Dulken et al., 2017), suggesting that neurospheres in culture may depend 
on inflammation-associated molecules for proper growth. In line with this notion, adult SVZ 
cells (microglia and neural stem/progenitors) in culture released IL-1, IL-4, IL-6, IL-10, 
and GM-CSF, whereas only IL-1 and GM-CSF were released by cortical cells (Ribeiro 
Xavier et al., 2015a) and similar results were found in postnatal SVZ microglia (Shigemoto-
Mogami et al., 2014). IL-4 and IL-10 are anti-inflammatory and act via phosphorylation of 
STAT6. In contrast to cortical microglia, SVZ microglia expressed nuclear pSTAT6 
suggesting an alternative state of activation (Ribeiro Xavier et al., 2015a). Thus, despite 
these interesting data, the field needs a more comprehensive understanding of how SVZ 
inflammation is regulated at the molecular level and on the feedback of inflammation onto 
SVZ cells. A few relevant examples are provided below and we argue that these concepts 
may prove useful in the therapautic prevention or management of SVZ cancer.
2.3.1. Galectin-3 expression and function in the SVZ 
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The studies described above show that SVZ microglia are unusual and that they 
secrete inflammation-regulating molecules in a pattern different from the rest of the CNS. 
Possibly however, it is not the microglia but SVZ NSCs and progenitors that play a major 
role in controlling inflammation in the niche. One example that supports this possibility is 
the inflammation-regulating protein Galectin-3 (Gal-3) which is expressed by NSCs, 
progenitors and ependymal cells in the SVZ but not by microglial cells (Comte et al., 
2011). Galectins are evolutionarily ancient recognizers of bacterial glycoproteins and 
regulate immune and cancer cell chemotaxis and apoptosis (Liu and Rabinovich, 2005). 
They are upregulated in animals and humans after brain injury and disease, and Gal-3 is 
generally understood to have pro-inflammatory functions (Hillis et al., 2016; James et al., 
2016; Young et al., 2014a). Therefore it is important to note that during homeostasis Gal-3 
is uniquely expressed in the SVZ at immunohistochemically detectable levels (Comte et 
al., 2011). Gain and loss of function studies showed that Gal-3 is necessary for neuroblast 
migration from the SVZ to the OB (Comte et al., 2011). Gal-3 function was shown to be 
important in the SVZ's response to TMEV, being necessary for immune cell infiltration into 
the SVZ, progenitor migration to demyelinated regions and SVZ proliferation (James et al., 
2016). Similarly, Gal-3 was also necessary for progenitor emigration induced by cuprizone 
from the SVZ into the demyelinated corpus callosum (Hillis et al., 2016). Given these 
studies collectively show that Gal-3 regulates multiple aspects of SVZ progenitor migration 
in health and disease, it will be interesting to explore its role in SVZ cancer infiltration into 
surrounding tissues. Gal-3 is essential for macrphage immigration into inflammed obese 
tissues (Li et al., 2016) and similarly is predicted to regulate macrophage infltration into 
SVZ cancers. A Gal-3 inhibitor (TD139) was well tolerated in Phase Ib/IIa clinical trials for 
idiopathic pulmonary fibrosis (Galecto Biotech) and should be tested in the context of SVZ-
originating brain cancers.
2.3.2. Polarity, the Hippo pathways and ASPP2 in inflammation and cancer 
Apicobasal cell polarity is a defining feature of SVZ NSCs which have an apical 
primary cilium extending between ependymal cells and in contact with CSF (Danilov et al., 
2009; Mirzadeh et al., 2008). This primary cilium is the location of sonic hedgehog (SHH) 
signaling and thereby regulates NSC activation in the ventral SVZ (Ahn and Joyner, 2005; 
Ihrie et al., 2011; Palma et al., 2005). The basal pole of the astrocyte-like SVZ NSCs in 
turn extend laterally to contact blood vessels (Mirzadeh et al., 2008). The basal processes 
regulate blood vessel diameter (Lacar et al., 2012), similar to astrocytic processes in the 
rest of the brain which regulate neurovascular coupling (Attwell et al., 2010; MacVicar and 
Newman, 2015). How inflammation affects this essential apicobasal cell polarity leading to 
SVZ tumorigenesis is poorly understood. Loss of apicobasal polarity is a central feature in 
epithelial mensenchymal transitions and escape of cancer cells from the primary tumor 
(Martin-Belmonte and Perez-Moreno, 2011; Moreno-Bueno et al., 2008; Royer and Lu, 
2011). Thus we predict that loss of apicobasal polarity is a prerequisite for NSC 
transformation into tumorigenic CSCs.
The  Hippo tumor suppressor pathway is important for normal tissue growth and 
homeostasis and is a key signalling pathway that maintains cell polarity (Harvey and 
Tapon, 2007). Inflammatory stimuli regulate Hippo pathway activity during regeneration 
(Wang et al., 2017b) but when polarity is lost this same process can lead to cancer. 
Interestingly, the Hippo pathway regulates primary cilia as well as cell division and 
differentiation in the brain (Huang et al., 2016; Orr et al., 2011). The main Hippo effector is 
the transcriptional coactivator Yes Associated Protein (YAP) which can interact with SHH 
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and promote growth of glioblastoma cell lines (Orr et al., 2011). AP activity in turn can be 
inhibited by the tumor suppressor neurofibromatosis 2 (NF2) in neural progenitor cells 
(Lavado et al., 2013; Orr et al., 2011). 
The Hippo pathway's role in inflammation can also be due to the control of tissue 
restoration. In a model of colitis, YAP does not affect normal tissue but it is necessary for 
healing, and this process can generate polyps and tumors when not balanced (Cai et al., 
2010; Kim et al., 2017). Moreover, the loss of the Hippo upstream activator Ras 
association domain family member 1A (RASSF1A) has been widely linked to tumor onset 
and is a specific prognostic factor in all brain cancers, especially GBM (Grawenda and 
O'Neill, 2015). It was proposed that in early inflammation, loss of RASSF1A causes 
binding of YAP to p73 promoting transcription of genes involved with apoptosis. In 
contrast, prolonged colitis promotes the binding of YAP to TEAD, which results in 
tumorigenesis (Gordon et al., 2013). A number of upstream inputs regulate the Hippo 
pathway and YAP in planar and apicobasal polarity including the Crbs complex, Fat 
cadherin, GPCR signalling, NF2, RASSF1, Sav1 and more recently the ASPP family via 
interaction with YAP1. 
ASPP2 (apoptosis-stimulating of p53 protein 2) activates p53 and is a 
haploinsufficient tumor suppressor expressed in NSC, ependymal and choroid plexus cells 
(Sottocornola et al., 2010; Turnquist et al., 2014). Lipopolysaccharide (LPS) activates 
ASPP2 in microglia, macrophages and astrocytes in a STAT1-dependent manner 
(Turnquist et al., 2014). In a maternal inflammation model, LPS induced ASSP2 
expression in the choroid plexus (Turnquist et al., 2014). Since ASPP2 is a tumor 
suppressor (Li et al., 2015), it is a good candidate for controlling cancer development in 
the SVZ. Human tissue in neurodegenerative disease exhibits enhanced ASPP2 
expression, whereas loss of ASPP2 results in enhanced inflammation, pointing to a model 
wherein ASPP2 is a "gatekeeper" of inflammation (Turnquist et al., 2014). ASPP2 also 
regulates NSC cell polarity which when disrupted leads to cancer like neuroblastic rosettes 
(Sottocornola et al., 2010) and we hypothesize that ASPP2 maintains the apicobasal 
polarity in SVZ NSCs and that loss of this polarity predisposes them to become 
tumorigenic.
3. Cancer Stem Cells Spring from the Subventricular Zone Stem Cell Niche
3.1.Brain cancers arising from the SVZ: clinical gliomas and ependymomas 
Localization, stem cell markers and molecular alterations indicate that a subset of 
gliomas emerge from stem or progenitor cells in the SVZ. Magnetic resonance imaging 
demonstrate that human gliomas can physically associate with the SVZ and this is strongly 
correlated with a poorer prognosis based on several criteria including survival rate, 
volume, recurrence pattern, invasiveness and progression (Bohman et al., 2010; Chen et 
al., 2015; Jafri et al., 2013; Kappadakunnel et al., 2010; Lim et al., 2007; Liu et al., 2016; 
Liu et al., 2017; Mistry et al., 2017b; Vergani et al., 2011; Young et al., 2011b). 
Glioblastomas in contact with the SVZ can migrate/infiltrate not just in the RMS but in 
multiple directions, a pattern followed by endogenous SVZ cells during embryonic and 
postnatal development (Adeberg et al., 2014b; Chen et al., 2015; Gupta et al., 2014; Lim 
et al., 2007). This could explain why periventricular tumors are more likely to be multifocal 
and present relapses that are not contiguous with the primary site. Finally, tumors in the 
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SVZ have a stem-like profile and are associated with specific genetic alterations that 
support cell growth, proliferation and survival via altered metabolic programs, centromere 
assembly, chromosome segregation, epigenetic modifiers and increased ribosomal 
biogenesis (Haskins et al., 2013; Jungk et al., 2016; Lin et al., 2017).
Stem and neural progenitor cell markers expressed in the SVZ are also found in 
gliomas physically associated with the SVZ, including glioblastomas (Bradshaw et al., 
2016). Periventricular astrocytomas of various grades express GFAP, nestin and vimentin 
and this expression correlates with invasiveness, possibly through increased levels of 
Annexin A2 (Brehar et al., 2015; Haskins et al., 2013). A proteomics analysis showed high 
expression levels of DCX, GFAP and vimentin in glioblastomas contacting the SVZ 
(Haskins et al., 2013). Besides, DCX+ cells were strongly correlated with c-Myc 
expression in those tumors and in the SVZ, suggesting a subpopulation of cells with 
possible growth advantage (Haskins et al., 2013). Olig2+ cells were found in proneural 
glioblastomas (Verhaak et al., 2010) and studies on animal models of gliomagenesis 
suggested Olig2+ cells in the SVZ as a potential origin of gliomas (Wang et al., 2009), 
including the proneural subtype (Lu et al., 2016). Interestingly, proneural and neural 
glioblastomas were closer to the SVZ than the other subtypes (Steed et al., 2016). 
Subependymomas may arise from multipotent cells in the SVZ and express glial and stem 
cell markers such as GFAP, Olig2 and Sox2 (D'Amico et al., 2017).
The SVZ stem cell niche can be tumorigenic in likely due at least in part to stem 
cells maintaining intrinsically active signalling pathways that are altered in tumors, making 
them susceptible to malignancy upon further stimuli. In the SVZ, pathways such as the 
EGFr promote proliferation and are altered in several gliomas due to the amplification of its 
receptor, contributing to malignant transformation (Sanai et al., 2005). The SHH pathway 
is vital in controlling stemness in the SVZ (Daynac et al., 2016) and can be altered and 
trigger tumors through canonical and non-canonical mechanisms (Alvarez-Buylla and Ihrie, 
2014; Clement et al., 2007; Sanai et al., 2005). 
3.2.The SVZ is a "growth factory" 
The specialized SVZ niche derives its unique identity and functions in large part due 
to the molecular environment it self-creates. Several neurotrophic growth factors are 
produced by NSCs and TAPs in the SVZ stem cell niche. Other cells present in this niche, 
such as ependymal cells, niche astrocytes, blood vessel endothelial cells, pericytes and 
microglia can also contribute to produce growth factors. These molecules function on NSC 
and TAPs in both autocrine and paracrine fashion and exert pleiotropic and redundant 
functions, regulating multiple cellular processes, such as growth, differentiation, survival 
and migration. The growth factors include brain-derived neurotrophic factor (BDNF), 
epidermal growth factor (EGF), fibroblast growth factor-2 (FGF-2), vascular endothelial 
factor (VEGF), insulin-like growth factor-1 (IGF-I), hepatocyte growth factor (HGF), and 
nerve growth factor (NGF) among others (Yu et al., 2016). Platelet-derived growth factor 
(PDGF), secreted by astrocytes and neurons, is a potent mitogen for oligodendrocyte 
progenitors (Noble et al., 1988; Raff et al., 1988; Richardson et al., 1988). Besides these 
molecules, cytokines produced in other sites of the body are able to cross the blood-brain 
barrier and induce proliferation and differentiation of NSC and TAPs in the SVZ; these 
include erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) (Yu et al., 
2016).
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These growth factors and cytokines signal through receptor tyrosine kinases and in 
cancer their aberrant activation affects proliferation, survival and metastasis (Lemmon and 
Schlessinger, 2010; Regad, 2015). Moreover, human gliomas themselves produce some 
of these growth factors (ex., PDGF-A, -B, -C, -D, bFGF) (Hermanson et al., 1992; 
Hermansson et al., 1988; Lokker et al., 2002; Takahashi et al., 1990; van der Valk et al., 
1997) and their cognate receptors (EGFR, PDGFR) (De Bustos et al., 2005; Hermanson et 
al., 1996; Hermanson et al., 1992; Hermansson et al., 1988; Toepoel et al., 2008; Torp et 
al., 1991; van der Valk et al., 1997) suggesting that paracrine/autocrine signaling could 
play an important role in proliferation and motility of SVZ cancer cells. Activation of the 
EGF and PDGF-pathways by gene amplification and/or overexpression are striking 
features of gliomas (Fleming et al., 1992), and EGFR amplification has been observed in 
35-70% of glioblastomas (Ohgaki and Kleihues, 2007; Okada et al., 2003; Sauter et al., 
1996), while PDGF and/or PDGFR amplification occurs in 13% of glioblastomas, >80% of 
oligodendrogliomas and in 50-100% of astrocytomas (Guha et al., 1995; Varela et al., 
2004). In pathogenic conditions, expression of the plethora of growth factors mentioned 
above can be dysregulated creating favorable circumstances for the initial expansion and 
selection of genetically mutated clones arising from SVZ stem or progenitor cells leading to 
cancer. 
3.3.SVZ stem cells as a potential source of brain cancer
3.3.1. SVZ cells can be "pushed" to a stem cell phenotype
A central axiom in biology is that development is unidirectional. Totipotent stem 
cells give rise to pluripotent and then multipotent cells which give rise to lineage committed 
progenitors that generate post-mitotic differentiated cells. Dedifferentiation and acquisition 
of developmentally less mature stem cell characteristics does not occur spontaneously. 
This has been challenged by artificially inducing developmental reversal via somatic cell 
nuclear transfer (SCNT) and induced pluripotent stem cell (iPSC) approaches. Both 
laboratory techniques show that adult cells or nuclei can be induced to acquire early stem 
cell characteristics via exposure to embryonic cytoplasm or transcription factors. Brain 
cells can acquire iPSC characteristics via Oct4 expression alone, one of the four 
"Yamanaka" transcription factors required for reprogramming (Kim et al., 2009a; Kim et al., 
2009b). In these experiments only a small percent of cells could be reprogrammed with 
Oct4 suggesting they may have been cells with immature characteristics such as SVZ 
cells. The development of SCNT and iPSC technologies spurred investigators to push the 
limits of unidirectional lineage progression with other approaches such as direct 
conversion. Direct phenotypic conversion bypasses intermediate mitotic events and 
induces phenotypic shifts (Arlotta and Berninger, 2014) within the same cell, showing that 
adult cells are indeed plastic and can acquire not only embryonic but alternative adult 
phenotypes. Other work has shown that outside the neurogenic niches astrocytes can be 
induced by injury and/or molecular regulation to re-enter the cell cycle and to become 
neurogenic (Buffo et al., 2008). These remarkable studies beg the question to what extent 
do cancer cells in the SVZ exhibit mutation or environment-induced "reprogramming" or 
"direct conversion"?
It is conceptually easier for less committed or undifferentiated cells to turn 
backwards and acquire stem cell characteristics (Zhou and Melton, 2008). In fact early 
work suggested that SVZ TAPs can acquire stem cell-like characteristics when exposed in 
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vivo to EGF (Doetsch et al., 2002). EGF exposure via Alzet mini-pumps in these 
experiments reduced expression of the proneurogenic transcription factor Dlx2 in transit 
amplifying progenitors. This is an important finding because more stem cells means there 
are more cells that could acquire a tumorigenic CSC phenotype. It is unclear however if 
endogenous levels of EGF can be sustained at high enough levels to induce acquisition of 
stem cell characteristics by SVZ cells, although this may occur in chronic disease. EGF 
signaling may also reverse the behaviour of doublecortin (Dcx+) neuroblasts. A subset of 
Dcx+ cells express the epidermal growth factor receptor (EGFr) and when these receptors 
were stimulated there was a 40% decrease in the number of migrating neuroblasts (Kim et 
al., 2009c). Reprogramming of SVZ NSCs has also been achieved via administration of 
Oct4, which resulted in them generating midbrain dopaminergic neurons (Deleidi et al., 
2011). Although SVZ cells can generate dopaminergic progenitors (Betarbet et al., 1996) 
that become interneurons in the olfactory bulb, these are quite different in ontogeny and 
function from the dopaminergic neurons generated by Deleidi and colleagues, whose 
experiments thus show acquisition of a more primordial NSC capacity. Ependymal cells 
are generally thought to be post-mitotic yet after models of stroke they also can re-enter 
the cell cycle and acquire a stem cell-like phenotype (Carlen et al., 2009; Young et al., 
2013). 
The reversal of developmental trajectory described above is reminiscent of cancer 
stem cells that arise from adult somatic cells. Theoretically any of the myriad cell types in 
the SVZ could acquire mutations and become tumorigenic and a variety of cells in the 
murine SVZ can become cancerous (Jackson et al., 2006). Regardless of which cell is the 
origin of any given SVZ cancer, we predict that dedifferentiation will usually accompany 
the process. The type of cell that becomes tumorigenic likely will influence the relative 
malignancy and the behaviour of the cells and this may partly explain glioblastoma 
heterogeneity. We hypothesize that SVZ NSC, when rendered tumorigenic would give rise 
to cancers with profound and long-lasting self-renewal and broad fate potential. 
Transformation of TAPs, in turn would result in highly proliferative tumors whereas 
transformation of neuroblasts would result in highly infiltrative lesions. These predictions 
can be tested by selectively introducing mutations into specific SVZ cell types. Thus we 
favour a model wherein the ultimate nature of the tumor is influenced by the origin of the 
CSC.
3.3.2. SVZ cancers modeled in mice 
 Animal models, including knock-in mutations, growth factor infusions and human-
rodent xenografts have created a variety of cancerous growths and revealed several 
molecular mechanisms resulting in tumorigenesis in the SVZ (Table 1) (Abel et al., 2009; 
Breunig et al., 2016; Feliciano et al., 2012; Zhou et al., 2011). The evidence for SVZ 
involvement in gliomagenesis gained traction with a series of in vivo experiments showing 
that malignant transformation preferentially occurs in proliferative areas of the brain (Sanai 
et al., 2005). Mouse models have been created showing that gliomas can be induced by 
forced expression of PDGF in the brain (Nazarenko et al., 2012). Excessive PDGFr 
activation in the SVZ of adult mouse brain, by exogenous administration of PDGF, induced 
the proliferation of PDGR-α-positive NSCs contributing to the generation of glioma-like 
lesions (Jackson et al., 2006). Similarly, adult white matter glial progenitors, expressing 
PDGF-B by retroviral transduction, cause the transformation of oligodendrocyte progenitor 
cells (OPC) and development of glioblastomas (Assanah et al., 2006). 
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Animal models using Cre-loxP or replication competent avian-like sarcoma (RCAS) 
virus / tumor virus receptor-A (tv-a) approaches show that mutations commonly found in 
gliomas create pre-lesions that evolve into gliomas when selectively induced in cells 
expressing stem cell promoters such as GFAP or Nestin. Using the Cre-loxP system Tp53 
null mice were further altered by conditional loss of Pten and/or Nf1 under the control of 
the GFAP promoter resulting in stem cell-like gliomas (Kwon et al., 2008; Zhu et al., 2005). 
The same alterations driven by the nestin promoter (tamoxifen-inducible Cre-ERT) 
generated high grade astrocytomas even when induced in adult animals (Alcantara 
Llaguno et al., 2009). Targeting the overexpression of Akt1 and Kras to GFAP and Nestin+ 
cells in the SVZ produced high grade gliomas (Abel et al., 2009; Holland et al., 2000; 
Marumoto et al., 2009). Significantly, the same alterations in differentiated cells in other 
brain regions did not induce tumorigenesis (Abel et al., 2009; Alcantara Llaguno et al., 
2009; Holland et al., 2000; Marumoto et al., 2009). Tp53 depletion and overexpression of 
PDGFA in the SVZ using RCAS/tv-a under the control of GFAP or nestin promoters 
generated tumors (Hambardzumyan et al., 2011) with proneural glioblastoma subtype 
characteristics (Connolly et al., 2017). Overexpression of PDGF in other areas of the brain 
was also able to produce tumors, suggesting it can act in different subpopulations of cells 
to give rise to gliomas (Connolly et al., 2017; Hambardzumyan et al., 2011). 
Another widely used model of glioma is treatment with the mutagen N-ethyl-N-
nitrosourea (ENU), resulting in SVZ tumors with stem cell marker expression (Garcia-
Blanco et al., 2016; Mennel and Simon, 1985). Cells became prone to generate tumors in 
the SVZ after Tp53 tumor suppressor loss, but additional stimuli such as ENU were 
necessary for full gliomagenesis (Gil-Perotin et al., 2006). The ENU carcinogen alterations 
included increased proliferation and angiogenesis through the activation of the AKT and 
ERK pathways (Bhaskara et al., 2006), β-catenin (Sareddy et al., 2009) and VEGF 
pathways (Bulnes and Lafuente, 2007). A subpopulation of cells isolated from the SVZ of 
mice transplacentally exposed to ENU became immortalized and it was found that they 
harbored homozygous deletion of INK4a/ARF (Savarese et al., 2005). Homozygous 
deletion of INK4a/ARF is a common event in classical glioblastomas and is highly 
associated with EGFR amplification (Verhaak et al., 2010). SVZ NSCs with deletion of 
Ink4a/Arf and constitutively active EGFR when orthotopically transplanted into mice 
generated tumors that expressed progenitor markers (Bachoo et al., 2002). In addition, the 
RCAS/tv-a system was used to show that the deletion of Ink4a/Arf in combination with 
activation of Kras and Akt in nestin-positive cells was able to generate glioblastomas 
(Uhrbom et al., 2002). Cells respond to the tumorigenic stimuli caused by Akt and H-Ras 
by increasing levels of Sox 5/6/2, and the deletion of those proteins in the SVZ increases 
the potential of Akt and H-Ras to drive gliomagenesis (Kurtsdotter et al., 2017). Together, 
these studies have revealed several inter-related mechanistic avenues and multiple SVZ 
cell sources for cancer generation. What is acutely missing is a comprehensive analysis of 
how inflammation is affected by these mouse models and if regulation of inflammation 
could influence their development.
3.3.3. IDH1 mutation as a model of cancer and inflammation in the SVZ 
More than 70% of brain tumors are gliomas, with glioblastoma multiforme (GBM) 
being most frequent and malignant. Mutations in the active site of isocitrate 
dehydrogenase (IDH1/2) have been identified in 80% of low grade gliomas and secondary 
GBMs, and persist in recurrent lesions (Dang et al., 2016). Thus IDH has been identified 
as a main driver gene in this disease, and its mutations are believed to be an early event 
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in gliomagenesis. How IDH1 mutations contribute to tumorigenesis is mostly unknown. 
This enzyme converts isocitrate to α-ketoglutarate (αKG), but when mutated, IDH1 
possess a novel enzymatic function that reduces αKG to 2-hydroxyglutarate (2HG). 2HG is 
thought to act as an oncometabolite, by inhibiting αKG-dependent enzymes. These include 
enzymes involved in DNA and histone demethylation among others (Dang et al., 2016). 
IDH1/2 mutant gliomas are characterized by genome-wide epigenetic changes, such as 
GpC island methylation (CIMP) and are associated with a better prognosis compared to 
patients with wild type IDH tumors. Recently Amankulor et al. showed that IDH1 mutations 
cause a reduction in leukocyte infiltration into gliomas, leading to a suppression of the 
tumor associated immune system. The authors suggest that this inhibited immune 
response contributes in part to the difference of aggressiveness of IDH-mutant tumors 
compared to their wild counterparts (Amankulor et al., 2017). Other studies showed that 
expression of mutant IDH or a treatment with 2HG reduced infiltration of cytotoxic CD8+ T 
lymphocytes within the tumor and levels of T cells-associated effector molecules and 
chemokines, such as CXCL10. Notably these effects were reversible by using IDH-C35, a 
specific inhibitor of mutant IDH1(Kohanbash et al., 2017). Along the same line, glioma 
cells and astrocytes expressing IDH-mutations are able to escape natural killer cell-
mediated cytotoxicity, by decreasing NKG2D ligand expression and IFN- secretion 
(Zhang et al., 2016). Consequently, these data suggest that mutant IDH is able to 
decrease the levels of immune surveillance, enabling tumor cells to escape it; this might 
allow tumor growth and progression. Recently, mice expressing mutant Idh1 in the SVZ 
were shown to develop features of gliomagenesis (Fig. 1) (Bardella et al., 2016). Mutant 
SVZ cells increased proliferation both in TAPs and in NSC, infiltrated into surrounding 
regions and expressed genes associated with proneural glioblastoma and Wnt signaling 
(Bardella et al., 2016). Given the SVZ stem cell niche has an atypical inflammatory 
response, it will be important to investigate the function of mutant-IDH on immune and 
inflammatory cells in this specific microenvironment, especially to evaluate a possible role 
during tumor initiation. 
3.4 SVZ cells can modulate cancer stem cells
The SVZ can generate tumors, but it is also important to consider how SVZ cells 
that are not transformed can modulate CSC and gliomagenesis. SVZ progenitors migrated 
towards striatal glioma in vivo and surrounded it and similarly SVZ cells in explants in vitro 
migrated towards glioma cells (Glass et al., 2005; Walzlein et al., 2008). This tropism 
decreased with age and was associated with increased cancer progression and decreased 
survival rates (Glass et al., 2005; Walzlein et al., 2008). Co-culture experiments also 
showed that SVZ cells limited tumor growth and increasd apoptosis of cancer cells (Glass 
et al., 2005).  Thus SVZ cells that emigrate to cancer may be beneficial.
Conversely, other evidence suggests that glioma cells migrate into the SVZ and 
become more dangerous. Human glioma cells injected into the striatium homed to the SVZ 
and then migrated to the OB via the RMS (Kroonen et al., 2011). The cancer cells that 
migrated into the SVZ had a strong tumorigenic capacity upon secondary transplantation 
(Kroonen et al., 2011) and had enhanced migratory responses to chemokine signalling in 
vitro (Goffart et al., 2015). SVZ cell-conditioned medium stimulated in vitro glioblastoma 
migration in a CXCL12/CXCR4 chemokine-dependent manner (Goffart et al., 2015). This 
signalling pathway may be a good target for adjunct therapy since glioblastoma cells that 
have migrated into the SVZ are resistant to radiotherapy (Goffart et al., 2017). Recently, a 
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pathogenic interaction between TAPs and glioma cells was demonstrated: TAPs produced 
chemoattractants toward which glioma cells homed. Amongst these SVZ TAP-secreted 
factors, the neurite outgrowth-promoting factor pleiotrophin along with its binding partners 
SPARC/SPARCL1 and HSP90B were the main mediators of this interaction (Qin et al., 
2017). Once arrived to the SVZ stem cell niche, glioma cells can then be encouraged to 
grow and form colonies by growth factors present in this specific microenvironment. 
Overall, these data are commensurate with the notion that the SVZ produces a variety of 
proteins including chemokines and growth factors that provide a chemoattractant and 
regulatory environment for cancer cells.
4. Interactions between Subventricular Zone Cancer Cells and Inflammation 
4.1. Inflammation can predispose tissues to mutations and cancer
Inflammation is driven by cells of the immune system and in physiological 
conditions is designed to fight infections and heal wounds. However, inflammation can 
also have tumor-promoting effects and has been widely recognized as one of the 
hallmarks of cancer (Hanahan and Weinberg, 2011). Inflammatory responses coordinate 
the cells in the tumor microenvironment, which include tumor cells, inflammatory cells, 
immune cells, endothelial cells, and extracellular matrix. Similar to the SVZ neurogenic 
niche, several cytokines, chemokines and growth factors are produced by cells in tumor 
microenvironments, resulting in complex cellular interactions and regulation of multiple 
cellular processes. In particular, inflammation produces molecules, such as growth factors 
that promote cell proliferation, survival factors that reduce cell death, pro-angiogenic 
factors and extracellular matrix proteases, that facilitate angiogenesis, invasion and 
migration, and signals activating epithelial to mesenchymal transition (Hanahan and 
Weinberg, 2011); altogether these responses can contribute to the onset and progression 
of cancer. 
However, cancer-related inflammation may also contribute to mutagenic load of 
tumor cells, by causing accumulation of random genetic alterations. Inflammatory cells can 
release reactive oxygen species and reactive nitrogen intermediates that are capable of 
inducing DNA damage and genomic instability in nearby cancer cells, accelerating their 
genetic evolution toward malignancy (Grivennikov et al., 2010). Inflammation may also 
cause genetic instability through another mechanism. By affecting the function or 
expression of mismatch repair genes or of their corresponding enzymes, it may disturb 
safeguarding of genomic integrity. These mechanisms include expression of HIF1 by 
inflammatory cytokines (TNF and IL-1, downregulation of MutS protein homolog 2 and 6 
(MSH2 and MSH6) by reactive oxygen and nitrogen species, direct oxidative inactivation 
of mismatch repair enzymes by hydrogen peroxide, and downregulation of mismatch 
repair family member MutL homolog 1 (MLH1), by nitric oxide (Colotta et al., 2009). Once 
the mismatch repair system has been inactivated, the rate of mutagenesis induced by 
inflammation can increase and genes harbouring microsatellites in their coding regions, 
included tumor suppressor genes can be inactivated (Colotta et al., 2009). Moreover 
cancer-related inflammation can alter cell cycle checkpoints, possibly causing 
chromosomal instability. Nitric oxide and its derivatives inhibit the function of the mitotic 
checkpoint p53 and are also associated with p53 mutations (Colotta et al., 2009). Growth 
factors and chemokines released by inflammatory cells in the tumor microenvironment can 
also increase expression of the transcription factor c-Myc. Expression of this oncogene 
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can increase the intrinsic mutation rate of cancer cells and impair genome integrity by 
different mechanisms, which include the induction of double strand breaks by the 
production of ROS (Colotta et al., 2009). Thus we hypothesize that the low-grade 
constitutive inflammation of the SVZ may predispose SVZ cells to become tumorigenic 
through accumulated mutations and thereby begin a feed forward cycle of inflammation-
driven cancer evolution. This hypothesis could be tested by determining the rate of 
somatic mutations in the SVZ compared to other brain regions.
4.2.Regulation of SVZ stem cells by inflammation
Inflammation triggered by the bacterial mimetic lipopolysaccharide (LPS), the viral 
mimetic polyinosinic-polycytidylic acid (polyI:C) or several cytokines was long-believed to 
be detrimental to neurognesis. Early studies showed that inflammation induced during 
adulthood diminishes SGZ neurogenesis which can be rescued by anti-inflammatory 
agents (Ekdahl et al., 2003; Monje et al., 2003). Maternal immune activation with LPS 
reduced ventricular proliferation in the developing cerebral cortex (Stolp et al., 2011). 
Likewise, exposure to polyI:C during embryonic development decreased NSCs and 
neuroblast populations in the adult SVZ (Liu et al., 2013). Persistent brain inflammation 
reduced the proliferation of NSCs and impaired neuroblast migration in the adult SVZ 
(Pluchino et al., 2008) while the anti-inflammatory cytokine IL-10 kept NSCs proliferative 
and undifferentiated in the adult SVZ (Perez-Asensio et al., 2013).
The one-sided view that inflammation simply reduces proliferation and neurogensis was 
challenged by studies suggesting that microglia and T cells can be beneficial for 
maintaining SGZ neurogenesis (Ziv et al., 2006). Recent studies have shown that 
microglia can also have positive effects on SVZ neurogenesis. Activated microglia support 
enhance SVZ neurogenesis through cytokine release whereas microglial inhibition 
reduced cytokine secretion and decreased SVZ neurogenesis during early postnatal 
development (Shigemoto-Mogami et al., 2014). Although microglial depletion increased 
proliferation in the adult SVZ, intact microglia were crucial for the survival and migration to 
the OB of adult SVZ neuroblasts (Ribeiro Xavier et al., 2015b). In another "positive" study, 
the pro-inflammatory cytokine TNFα increased NSC proliferation in adult SVZ neurosphere 
culture (Widera et al., 2006).  
Taken together, inflammation can result in positive or negative effects on SVZ 
neural stem cells and neurogenesis. The data suggest that the effects of inflammation in 
the SVZ are difficult to predict. This binary effect of inflammation likely depends on a 
number of factors such as the type of inflammatory stimuli, cell types involved in the 
response and the time and context of the inflammatory insult. These factors may also 
influence whether microglia acquire an M1 phenotype (cytotoxic) or an M2 phenotpye 
(neuroprotective) resulting in differential effects on SVZ neural stem cells. Classically 
activated M1 microglia can induce astrocytes to become neurotoxic via Il-1, TNF and 
C1q (Liddelow et al., 2017). This form of astrocytic toxicity has been implicated in 
neurodegenerative disease and it will be important to determine if SVZ microglia stimulate 
SVZ NSC or niche astrocytes in a similar manner in the context of cancer. Whether 
cancer-induced inflammation has positive or negative effects on SVZ cell proliferation and 
indeed on SVZ CSC themselves should also be resolved in order to develop viable 
therapeutic options.
4.3.Drugs for inflammation and SVZ cancer
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Multiple pharmacological approaches are becoming feasible for targeting SVZ CSC. 
A huge wealth of information has emerged on the molecular mechanisms regulating many 
aspects of SVZ neurogenesis. Given that these mechanisms are often co-opted by SVZ 
cancers, target discovery approaches seem viable. Alternatively, phenotypic screen-based 
drug discovery seeking to limit SVZ proliferation, increasing differentiation or increasing 
apoptosis, could be developed to tackle periventricular tumors (Moffat et al., 2017). 
However, this has to be done carefully as hippocampal neurogenesis is important for 
memory and hypothalamic neurogenesis may be important for longevity (Zhang et al., 
2017). Drugs have in fact been found that promote neuronal differentiation (Wurdak et al., 
2010). One example that could be used to treat SVZ cancers is the small molecule 
KHS101, which inhibits proliferation of progenitor cells and favors neuronal differentiation 
by allowing the activity of the transcriptional factor ARNT2 (Wurdak et al., 2010). Drugs are 
being developed to stimulate neurogenesis for neurodegenerative disease, although, 
those that increase survival (Pieper et al., 2010) or activate stem cells would not be 
appropriate for cancer. 
Instead of targeting neural CSC proliferation or invasion, drugs targeting 
inflammation should be considered. Several drugs which target inflammation are beneficial 
in multiple sclerosis (Dendrou et al., 2015) and could be repurposed for cancer therapy. 
Epidemiologic studies have shown that anti-inflammatory use is protective against 
gliomas, for example regular use of non steroidal anti-inflammatories reduced glioma risk 
by 33% (Scheurer et al., 2008; Sivak-Sears et al., 2004). In gliomas,TGF-β can be 
secreted by cells including microglia and macrophages and, through abnormal signalling, 
can have either pro- or anti-tumorigenic actions particularly on CSC (Han et al., 2015; 
Joseph et al., 2013). Several approaches aiming to target TGF-β signaling in gliomas have 
been tested and acheived encouraging results (Han et al., 2015; Joseph et al., 2013). For 
example, the TGF-β-activated kinase-1 (TAK1) is known to regulate inflammation in 
diverse types of cancer and in multiple sclerosis (Sakurai, 2012). Conditional TAK1 
depletion specifically in microglia reduces central nervous system inflammation and is 
helpful in multiple sclerosis (Goldmann et al., 2013). As well, TAK1 inhibitors have proven 
effective in cancer therapy (Sakurai, 2012; Totzke et al., 2017). Recently, the inhibitor 
Takinhib was found to have high specificity for both autophosphorylated and non-
phosphorylated TAK1 and induced cell death in metastatic breast cancer cells (Totzke et 
al., 2017). 
Anti-inflammatory drugs are important candidates for treatment of gliomas due to 
their ability in vitro and in vivo to supress proliferation and migration and to promote 
apoptosis. Sulfasalazine, is effective in inflammatory bowel disease and targets human 
glioma CSC in a xenograft model by inhibiting the cystine–glutamate transporter (xCT) and 
promoting caspase-mediated apoptosis (Chung et al., 2005). Sulfasalazine does not cross 
the blood-brain barrier, although it successfully increased survival of orthotopic 
transplanted xenografts when locally delivered (Haryu et al., 2018). In another positive 
development, a range of plant-derived anti-inflammatory drugs are being proposed as 
treatments because of their anti-glioma activity and their capacity to cross the blood-brain 
barrier. Withaferin A, Dehydrocostus lactone and Evodiamine are examples of compounds 
which presented encouraging results via mechanisms involving inflammatory pathways 
(Dhami et al., 2017; Hou et al., 2017; Marlow et al., 2017; Wang et al., 2017a; Wu et al., 
2017). Finally, Gal-3 is known for its role in activating microglia and it can be 
overexpressed in gliomas (Liu and Rabinovich, 2005). As mentioned above, the Gal-3 
inhibitor TD139 (Galecto Biotech) has been tested in idiopathic pulmonary fibrosis with 
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good results and it would be particularly interesting to analyze its effects in the context of 
periventricular gliomas. 
Another way to approach inflammation in brain tumors is by specifically inhibiting 
glioma-associated macrophages and microglia (GAMs) which contribute to diverse 
aspects of tumorigenesis (Roesch et al., 2018). In fact, several drugs that target microglia 
are already being tested in preclinical and clinical trials (Roesch et al., 2018). Inhibition of 
GAM Mer tyrosine kinase receptor (MerTKr) by UNC2025 combined with fractionated 
external beam radiotherapy, increased mouse survival (Wu et al., 2018). Finally, 
minocycline, a p38 MAP kinase inhibitor, supresses GAM activity and has been proposed 
as an adjuvant treatment for gliomas (Markovic et al., 2011), however it must be 
approached with caution as it can also induce neuronal death and impair SVZ neuro and 
gliogenesis (Inta et al., 2017). 
Ependymal cells are a convenient target for gene therapy designed to influence 
SVZ gliomagenesis. Over a decade ago an adenoviral gene delivery strategy was 
developed in rats as proof-of-principle, with a secreted glycoprotein being selectively 
targeted to ependymal cells and expression sustained for an extended period of time 
(Bajocchi et al., 1993). Since then ependyma-specific transcription factors such as FoxJ1 
(Jacquet et al., 2009) have been discovered and these can be co-opted via promoter 
specific driven constructs for selective ependymal cell targeting. Recent work in mouse 
has shown that ependymal viral targeting with the human lysosomal enzyme arylsulfatase 
A resulted in expression of up to one year (Yamazaki et al., 2014). Ependymal cell 
targeting has also been used to treat a number of neurodegenerative diseases and offers 
the advantage of localizing increased gene expression to the interior of the brain, avoiding 
systemic effects (Sun et al., 2017). Ependymomas themselves are conveniently located for 
gene therapy via the lateral ventricles. However in this case other promoter-based 
targeting strategies than FoxJ1 may have to be chosen given that FoxJ1 expression 
decreases in ependymomas (Abedalthagafi et al., 2016). Mcidas and GemC1 are 
upstream of FoxJ1 and essential in ependymal cell differentiation (Kyrousi et al., 2015) 
and may be good molecular targets for ependymoma gene therapy. 
Discovery of the brain lymphatic system lends great hope for CNS drug delivery. 
Fortunately the SVZ lines the ventricular system which is an integral part of the brain's 
lymphatic drainage system (Engelhardt et al., 2017; Sun et al., 2017). The olfactory 
system is also known to be part of the brain lymphatic system with CSF egressing into the 
nasal cavity. However proteins can travel in the opposite direction from the nasal 
epithelium to the brain and several preclinical studies have shown therapeutic efficacy via 
this route (Fletcher et al., 2009; Lin et al., 2009; Scafidi et al., 2014). Interestingly, 
intranasal delivery can also provide therapeutic benefit via modulation of inflammation (Cai 
et al., 2011; Jiang et al., 2011). Although controversial for many years, the nasal route of 
administration of drugs for CNS therapy is becoming well established and accepted (Sun 
et al, 2017). This route of administration may be exceptionally well-suited for targeting SVZ 
cancers.
Conclusions 
A huge wealth of information about cell phenotypes and molecular mechanisms regulating 
neurogenesis in the SVZ has been generated in the last twenty years. This is 
advantageous in terms of helping the field understand how these cells and processes may 
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be transformed and become tumorigenic. Glioblastomas and other cancers can arise from 
the SVZ and can also be modeled in the niche in animals. The role of inflammation in this 
process is still poorly understood, but deserves in-depth study. This is likely to be complex 
as inflammation can have both positive and negative effects on SVZ proliferation. The 
regulation of SVZ inflammation in the context of pathology can differ dramatically 
compared to other brain regions. Once more in-depth information will be acquired on the 
specific roles of inflammation in different SVZ cancers, therapeutic interventions can be 
rationally considered. The SVZ is rather more accessible than other brain regions by virtue 
of its location next to the ventricles and thus the treatment of SVZ cancers may be more 
tractable than cancer found in other parts of the brain. 
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Figure Legends
Figure 1. The Idh1R132H mutation knocked into the SVZ niche induces gliomagenesis. A) 
Control SVZ next to the lateral ventricle (lv) shows a typical distribution of GFAP+ (red), 
label-retaining BrdU+ cells (white) and acutely proliferating Ki67+ cells (green). B,C) These 
populations increased dramatically in the SVZ and striatum upon tamoxifen-induced 
conditional knockin of the  Idh1R132H mutation into nestin+ SVZ cells.  D) Schematic of 
different cell types in the SVZ and their response to the IDH1 mutation. Note that it is not 
yet determined whether one type of TAP gives rise to lineage committed progenitors (as 
depicted) or if multiple distinct TAPs exist. Adapted from Bardella et al., 2016.
Figure 2. Glioma (Gl) associated with the human SVZ. The location of the contralateral 
SVZ is outlined in red and indicated with an arrow. Note that the glioma is pushing the 
lateral ventricle medially and the caudate nucleus (Cn) laterally. This glioma is likely 
heterogeneous and composed of many different types of cells as suggested by the 
multiple hues within it. From: 
https://library.med.utah.edu/WebPath/CNSHTML/CNS132.html
Figure 3. Schematic showing major points in the review about the relationships between 




Table 1. Cancer models induced in rodent SVZ 
Experimental approach, 
molecular mechanism Main result
Implication, 
importance Reference
p53-/- and p53fl/fl mice ± oncogenic 
ENU-induced mutations.
Loss of p53 function 
alone increases 
proliferation and 
differentiaton rate but is 
insufficient for 
transformation.




(Gil-Perotin et al., 2006)
PTEN loss of function induced by 
PTEN+/-  introduced into a 
Nf1/p53 astrocytoma model in 
mice.




Infiltration into various 
brain regions suggests an 
SVZ origin for the tumors.
(Kwon et al., 2008)
Nestin-creERT2 mice bred with 
Nf1flox/+;p53flox/flox;Ptenflox/+ 
or Nf1flox/flox;p53flox/flox and 
adult mice treated with tamoxifen 
at 4 weeks of age. 
Tumor suppressor 
inactivation in SVZ is 
both necessary and 
sufficient to induce 
astrocytoma formation.
All TMX mice developed 
astrocytomas. A 
pretumorigenic cell 
population in vitro showed 
growth advantage.
(Alcantara Llaguno et al., 
2009)
 A p53 in-frame deletion mutation 
achieved by crossing GFAP-cre 
mice with p53 foxed mice.
Detectable mutant p53 
first seen in SVZ NSC, 
progressing to  Olig2+ 
transit amplifying 
progenitor like cells 
leading to astrocytma.
P53 loss by itself 
insufficient for 
tumorigenesis but allows 
subsequent mutations. 
(Wang et al., 2009)
Lentiviral induction of mutant H-
Ras or Akt in GFAP+ cells ± 
Tp53+/– mutations using Cre-lox 
mice.
Massive tumours 
induced in SVZ or SGZ 
but not inthe cerebral 
cortex.
Convenient technique for 
introducing oncogenic 
mutations in specific cell 
type CRE driver lines.
(Marumoto et al., 2009)
Activated Ras and Akt introduced 
into mouse SVZ or astrocytes.
Both molecules needed 
for transfrmation.
Induced high grade 
gliomas only via SVZ 
cells, not astrocytes.
(Holland et al., 2000)




This study suggests that 
tumor cells can derive 
from NSC, after being 
transformed by oncogenic 
K-rasG12.
(Abel et al., 2009)
SVZ electroporation in mice of 
mutant Ras and transposons for 
permanent integration.
Depleted NSC and 
upregulation of ETS 
factors.
Demonstrated that 
blocking ETS inhibits 
glioma formation.
(Breunig et al., 2016)
Sox5flox/flox and Sox6flox/flox mice 
were injected with lentiviruses 
expressing CRE, HRas and AKT.




Shows that Sox5/6/21 
prevent HRAS and AKT 
induced oncogenic 
transformation.
(Kurtsdotter et al., 2017)
Infusion of PDGF in mice 
activated the PDGFR.
Generation of glioma-
like hyperplasias and 
blockade of 
neurogenesis.
One of the first papers to 
link fate choice with 
tumorigenesis.
(Jackson et al., 2006)
Combination of mathematical 
modeling and RCAS/tv-a PDGF 
overexpression in murine GFAP+ 
SVZ cells.
Modeling predicts TAP 




otherwise a NSC origin.
PDGF OE in GFAP SVZ 
cells suggests modelling 
is correct.
(Hambardzumyan et al., 
2011)
Tsc1 loxP mice induced loss-of-
function by crossing with Nestin-





giant cell astrocytomas. 
More severe phenotype 
in Nestin-Cre mice.
Phenotype hypothesized 
to be due to abnormal 
migration.
(Zhou et al., 2011)
Tsc loss of function achieved with 
floxed mice crossed with Nestin-







Suggest that emigration 
may contribute to 
psychiatric symptoms of 
tuberous sclerosis.
(Feliciano et al., 2012)
Tamoxifen inducible knockin of








First viable in vivo model 
of this common human 
GBM mutation. First 
mouse model showing 
that expression of  
Idh1R132H in mouse SVZ 
induces gliomagenesis.
(Bardella et al., 2016)
In utero ENU exposure in rats 
caused homozygous deletion 
spanning the INK4a/ARF locus. 
Induced transformation 
as indicated by blocked 
senescence.
Transformed SVZ cells 
model glioma precursors 
and can be a reservoir for 
further genetic/epigenetic 
hits leading to glioma.
(Savarese et al., 2005)
ASPP2, apoptosis-stimulating protein of p53 with signature sequences of 
ankyrin repeat-, SH3 domain-, and proline-rich region-containing protein 2; 
CD, complement of differentiation; CNS, central nervous system; CP, choroid 
plexus; CSC, cancer stem cell; CSF, cerebrospinal fluid; EGF, epidermal 
growth factor; EGFr, epidermal growth factor receptor; EPO, erythropoeitin; 
FGF2, Fibroblast growth factor 2; GBM, glioblastoma multiforme, GFAP, glial 
fibrillary acidic protein; G-CSF, granulocyte colony-stimulating factor; HGF, 
hepatocyte  growth factor; IDH1, isocitrate dehydrogeniase 1; IFN- gamma 
interferon; IGF-1, insulin growth factor-1; IL-10, interleukin 10; iPSC, induced 
pluripotent stem cell; NSC, neural stem cell; OCT4, octamer-binding 
transcription factor 4; PDGF, platelet-derived growth factor; PDGFr, platelet-
derived growth factor receptor; RCAS, replication competent avian-like 
sarcoma; RMS, rostral migratory stream; ROS, reactive oxygen species; 
SCNT, somatic cell nuclear transfer; SDF-1, stromal cell derived factor-1; 
SHH, sonic hedgehog; SVZ, subventricular zone; TAP, transit amplifying 
progenitor; TMEV, Thelier's murine encephalomyelitis virus; TNFα, tumor 
necrosis factor-alpha; VEGF, vascular endothelial growth factor.
